Showing results (81-90 of 133) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2005
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphomaQin C Ryan, Donna Headlee, Milin Acharya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomasArun Rajan, Ronan J Kelly, Jane B Trepel, et al.
Cancer Medicine|October 8, 2022
Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxelGuillaume Joe Pegna, Min-Jung Lee, Cody J Peer, et al.
Cell Cycle (Georgetown, Tex.)|September 1, 2012
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cellsAki Iwai, Dimitra Bourboulia, Mehdi Mollapour, et al.
Blood|July 20, 2002
Regulation of leukemic cell adhesion, proliferation, and survival by beta-cateninEun Joo Chung, Sang-Gu Hwang, PhuongMai Nguyen, et al.
Cancer Biology & Therapy|September 3, 2005
A phase II study of perifosine in androgen independent prostate cancerEdwin M Posadas, James Gulley, Philip M Arlen, et al.
Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Translational Lung Cancer Research|August 25, 2021
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignanciesMary Zhang, Julie A Hong, Tricia F Kunst, et al.
Nature Communications|June 24, 2021
Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancerNitin Roper, Moises J Velez, Alberto Chiappori, et al.
The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
Pageof 14